Roche In-Licenses Galaxy Biotech’s Preclinical FGF2 Antibody Programme

Abstract

Roche has licensed global rights to Galaxy Biotech’s preclinical-stage antibodies that target fibroblast growth factor 2 (FGF2), a key target in cancer metastasis. Roche will assume responsibility for the development and commercialisation of the programme and will pay Galaxy US$8 M upfront as well as potential milestone payments and royalties. The deal comes 3 months after Takeda Pharmaceutical terminated its licence agreement with Galaxy for the anti-HGF (hepatocyte growth factor) monoclonal antibody HuL2G7.